Controlled Parenteral Formulations: An Efficacious and Favourable Way to Deliver the Anti-psychotic Drugs

Author(s): Harshita Gupta, Rutu Panchal, Niyati Acharya, Priti Jignesh Mehta*

Journal Name: Current Psychiatry Research and Reviews
Formerly Current Psychiatry Reviews

Volume 16 , Issue 1 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

The current paradigm of pharmaceutical formulations is focused on the controlled & sustained delivery of a drug for the management of chronic impairments. Since these diseases need daily and multiple intakes of the drug (i.e., twice or thrice a day) and missing a single dose, leads to the poor therapeutic window which governs unpleasant pharmacological response and ultimately patient in-compliance. All over the world, millions of patients are suffering from life-threatening diseases; one of which is “psychosis”, which immensely requires prolong and sustain release of the drug. Moreover, mainstay lacuna with antipsychotic medication is the reoccurrence of the symptoms, and patient adherence on the therapy has been observed. These issues attract scientists to formulate the Controlled Parenteral Antipsychotic (CPA). As per the literature search, significant work has been performed on the development of Novel Controlled Parenteral Formulations (CPFs) for the treatment of psychosis and especially focus has been given to microsphere, esterification, nanoformulation, and salt-based formulation. Reports revealed that all of the above-mentioned formulations have shown enormous potential to enhance the duration of a drug in the body for a longer period in a controlled manner. The development of a drug in any form has shown a great impact on the patient’s life, with tremendous productivity in the Pharma Market. As well as, this has raised the hope to get more efficacious results of both the categories i.e., typical & atypical antipsychotics and limiting the drawbacks of conventional antipsychotic drug delivery. Controlled formulations have also shown the prominent solutions to handle one of the major obstacles that arises due to the Biopharmaceutical Classification System (BCS). Drugs belonging to any of the BCS class can be utilized now with the idea of CPF. In this context, the current paper relies on CPA’s strengths, weaknesses, opportunities, and challenges followed by a compilation of attempt made by scientists on its formulations (microspheres, salt-based, and nanoformulation) which will be one-stop-shop for the researchers working globally in this field to make better improvement on the existing options for psychosis. In summary, this review explains the concept of CPA as a promising option to treat psychosis.

Keywords: Controlled parenteral antipsychotic, biopharmaceutical classification system, controlled parenteral formulation, long-acting parenteral, microspheres, nanoparticle, salt formation.

[1]
Gulati N, Gupta H. Parenteral drug delivery: a review. Recent Pat Drug Deliv Formul 2011; 5(2): 133-45.
[http://dx.doi.org/10.2174/187221111795471391] [PMID: 21453250]
[2]
Shahiwala A, Mehta TA, Momin MM. Parenteral drug delivery systems. In vitro and in vivo tools in drug delivery research for optimum clinical outcomes, Ambikanandan M, Aliasgar S, Eds. CRC Press 2018; pp: 301-36.
[3]
Chien Y. Novel drug delivery systems 1991.
[4]
Bari H. A prolonged release parenteral drug delivery system-an overview. Int J Pharm Sci Rev Res 2010; 3(1): 1-11.
[5]
Agrawal M, Limbachiya M, Sapariya A, Patel G. A review on parenteral controlled drug delivery system. Int J Pharm Sci Res 2012; 3(10): 3657.
[6]
Sheikh AA. Injectable controlled release drug delivery systems. Asian J Pharm 2016; 10(4): S464-71.
[7]
Park K. Controlled drug delivery systems: past forward and future back. J Control Release 2014; 190: 3-8.
[http://dx.doi.org/10.1016/j.jconrel.2014.03.054] [PMID: 24794901]
[8]
Muralidhar P, Bhargav E. Controlled release injectable drug delivery: an over view. Asian J Biomater Res 2017; 3(1): 6-15.
[9]
Jantzen GM, Robinson JR. Sustained-and controlled-release drug delivery systems. Drugs Pharm Sci 2002; 121: 501-28.
[10]
Niraj VK, Srivastava N. Sustained and controlled drug delivery system-as a part of modified release dosage form. Int J Res Pharm Nano Sci 2015; 4(5): 347-64.
[11]
Hoffman AS. The origins and evolution of “controlled” drug delivery systems. J Control Release 2008; 132(3): 153-63.
[http://dx.doi.org/10.1016/j.jconrel.2008.08.012] [PMID: 18817820]
[12]
Kostanski JW, Matsuda T, Nerurkar M, Naringrekar VH. inventor; Otsuka Pharmaceutical Co Ltd Curr., assignee. Controlled release sterile injectable aripiprazole formulation and method 2017.United States patent US8030313B2. 2011.
[13]
Burgess DJ, Wright JC. An introduction to long acting injections and implants In:Long Acting Injections and Implants. Wright JC, Burgess DJ, Eds. New York. Springer Science & Business Media 2012; pp. 1-9.
[http://dx.doi.org/10.1007/978-1-4614-0554-2_1]
[14]
Kalyani M, Surendra P, Sirisha V. Parenteral controlled drug delivery system. Int J Res Pharm Nano Sci 2013; 2: 572-80.
[15]
Altamura AC, Sassella F, Santini A, Montresor C, Fumagalli S, Mundo E. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs 2003; 63(5): 493-512.
[http://dx.doi.org/10.2165/00003495-200363050-00004] [PMID: 12600227]
[16]
Ansel HC, Popovich NG, Allen LV. Pharmaceutical dosage forms and drug delivery systems. Baltimore: Williams & Wilkins 1995.
[17]
Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. Br Med Bull 2015; 114(1): 169-79.
[http://dx.doi.org/10.1093/bmb/ldv017] [PMID: 25957394]
[18]
Mackin P, Thomas SHL. Atypical antipsychotic drugs. BMJ 2011; 342: d1126.
[http://dx.doi.org/10.1136/bmj.d1126] [PMID: 21378070]
[19]
Tandon R, Jibson MD. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann Clin Psychiatry 2002; 14(2): 123-9.
[http://dx.doi.org/10.3109/10401230209149099] [PMID: 12238737]
[20]
Nasrallah HA. Triple advantages of injectable long acting second generation antipsychotics: Relapse prevention, neuroprotection, and lower mortality. Schizophr Res 2018; 197: 69-70.
[http://dx.doi.org/10.1016/j.schres.2018.02.004] [PMID: 29506767]
[21]
Second-generation long-acting injectable antipsychotic agents: an overview. Drug Ther Bull 2012; 50(9): 102-5.http://dtb.bmj.com/content/50/9/102
[22]
Chue P, Emsley R. Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics. CNS Drugs 2007; 21(6): 441-8.
[http://dx.doi.org/10.2165/00023210-200721060-00001] [PMID: 17521224]
[23]
Dixit N, Maurya SD, Sagar BPS. Sustained release drug delivery system. Ind J Res Pharm Biotechnol 2013; 1(3): 305.
[24]
Shi Y, Li LC. Current advances in sustained-release systems for parenteral drug delivery. Expert Opin Drug Deliv 2005; 2(6): 1039-58.
[http://dx.doi.org/10.1517/17425247.2.6.1039] [PMID: 16296808]
[25]
Sudhakar M, Kancharla R, Rao VU. A review on sustained release injectable depot drug delivery systems. Int J Adv Pharm Sci 2013; 4: 142-58.
[26]
Moreno-Küstner B, Martín C, Pastor L. Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses. PLoS One 2018; 13(4)e0195687
[http://dx.doi.org/10.1371/journal.pone.0195687] [PMID: 29649252]
[27]
Agid O, Foussias G, Remington G. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Expert Opin Pharmacother 2010; 11(14): 2301-17.
[http://dx.doi.org/10.1517/14656566.2010.499125] [PMID: 20586707]
[28]
Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol 1998; 8(1): 55-66.
[http://dx.doi.org/10.1016/S0924-977X(97)00045-X] [PMID: 9452941]
[29]
Dencker SJ, Axelsson R. Optimising the use of depot antipsychotics. CNS Drugs 1996; 6(5): 367-81.
[http://dx.doi.org/10.2165/00023210-199606050-00004]
[30]
Davis JM, Metalon L, Watanabe MD, Blake L. Depot antipsychotic drugs. Drugs 1994; 47(5): 741-73.
[http://dx.doi.org/10.2165/00003495-199447050-00004] [PMID: 7520856]
[31]
Comaty JE, Janicak PG. Depot neuroleptics. Psychiatr Ann 1987; 17(7): 491-6.
[http://dx.doi.org/10.3928/0048-5713-19870701-14]
[32]
Gary JR, Martha EA. Depot neuroleptic therapy: clinical considerations. Canadian J Psy 1995; 40(3): 5-11.
[http://dx.doi.org/10.1177/070674379504003S02]
[33]
Sreeraj VS, Shivakumar V, Rao NP, Venkatasubramanian G. A critical appraisal of long acting injectable antipsychotics: Translating research to clinics. Asian J Psychiatr 2017; 28: 57-64.
[http://dx.doi.org/10.1016/j.ajp.2017.03.018] [PMID: 28784398]
[34]
Masand PS, Gupta S. Long-acting injectable antipsychotics in the elderly: guidelines for effective use. Drugs Aging 2003; 20(15): 1099-110.
[http://dx.doi.org/10.2165/00002512-200320150-00003] [PMID: 14651433]
[35]
Lycett-Smith M, Azar M, Code M. Guidance on the administration to adults of oil-based depot and other long-acting intramuscular antipsychotic injections
[36]
Bosanac P, Castle DJ. Why are long-acting injectable antipsychotics still underused? BJPsych Adv 2015; 21(2): 98-105.
[http://dx.doi.org/10.1192/apt.bp.114.013565]
[37]
Kane JM. Utilization of long-acting antipsychotic medication in patient care. CNS Spectr 2006; 11(12)(Suppl. 14): 1-7.
[http://dx.doi.org/10.1017/S1092852900025852] [PMID: 17146411]
[38]
Remenar JF. Making the leap from daily oral dosing to long-acting injectables: lessons from the antipsychotics. Mol Pharm 2014; 11(6): 1739-49.
[http://dx.doi.org/10.1021/mp500070m] [PMID: 24679167]
[39]
Baweja R, Sedky K, Lippmann S. Long-acting antipsychotic medications. Curr Drug Targets 2012; 13(4): 555-60.
[http://dx.doi.org/10.2174/138945012799499785] [PMID: 22250654]
[40]
Kane JM, Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry Suppl 2009; 52(S52): S63-7.
[http://dx.doi.org/10.1192/bjp.195.52.s63] [PMID: 19880920]
[41]
Brissos S, Veguilla MR, Taylor D, Balanzá-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol 2014; 4(5): 198-219.
[http://dx.doi.org/10.1177/2045125314540297] [PMID: 25360245]
[42]
Naber D. Olanzapine pamoate for the treatment of schizophrenia. Expert Opin Pharmacother 2011; 12(4): 627-33.
[http://dx.doi.org/10.1517/14656566.2011.553193] [PMID: 21254860]
[43]
Motiwala FB, Siscoe KS, El-Mallakh RS. Review of depot aripiprazole for schizophrenia. Patient Prefer Adherence 2013; 7: 1181-7.
[PMID: 24265550]
[44]
Martinez MN, Khan MA. Regulatory issues and challenges associated with the development of performance specifications for modified release parenteral products.In: Long Acting Injections and Implants,. Wright. J. C, Burgess. D. J, Eds.. Springer Science & Business Media 2012; pp. 505-35.
[http://dx.doi.org/10.1007/978-1-4614-0554-2_24]
[45]
Martinez M, Rathbone M, Burgess D, Huynh M. In vitro and in vivo considerations associated with parenteral sustained release products: a review based upon information presented and points expressed at the 2007 Controlled Release Society Annual Meeting. J Control Release 2008; 129(2): 79-87.
[46]
Brahmankar DM, Jaiswal SB. Biopharmaceutics and pharma-cokinetics: a treatise. Vallabh Prakashan 2005.https://books.google.co.in/books?id=PVCEMwEACAAJ
[47]
Rizvi SAA, Saleh AM. Applications of nanoparticle systems in drug delivery technology. Saudi Pharm J 2018; 26(1): 64-70.
[http://dx.doi.org/10.1016/j.jsps.2017.10.012] [PMID: 29379334]
[48]
Wang Y, Burgess DJ. Microsphere technologies. In:Long Acting Injections and Implants. Wright. J. C, Burgess. D. J, Eds.. Springer Science & Business Media 2012; pp. 167-94.
[49]
Sahil K, Akanksha M, Premjeet S, Bilandi A, Kapoor B. Microsphere: a review. Int J Res Pharm Chem 2011; 1(4): 1184-98.
[50]
Dold M, Samara MT, Li C, Tardy M, Leucht S. Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders 2015.
[http://dx.doi.org/10.1002/14651858.CD009831.pub2]
[52]
Cheng Y-H, Illum L, Davis SS. A poly(D,L-lactide-co-glycolide) microsphere depot system for delivery of haloperidol. J Control Release 1998; 55(2-3): 203-12.
[http://dx.doi.org/10.1016/S0168-3659(98)00056-X] [PMID: 9795060]
[54]
Nahata T, Saini TR. D-optimal designing and optimization of long acting microsphere-based injectable formulation of aripiprazole. Drug Dev Ind Pharm 2008; 34(7): 668-75.
[http://dx.doi.org/10.1080/03639040701836545] [PMID: 18608461]
[55]
Talegaonkar S, Mittal A, Parmar S, Aqil M. Aripiprazole loaded polymeric biodegradable microspheres: formulation and in vitro characterization. J Dispers Sci Technol 2009; 30(8): 1198-202.
[http://dx.doi.org/10.1080/01932690802701788]
[56]
Hiraoka S, Uchida S, Namiki N. Preparation and characterization of high-content aripiprazole-loaded core-shell structure microsphere for long-release injectable formulation. Chem Pharm Bull (Tokyo) 2014; 62(7): 654-60.
[http://dx.doi.org/10.1248/cpb.c14-00110] [PMID: 24990503]
[57]
[58]
Möller H-J. Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives. Drugs 2007; 67(11): 1541-66.
[http://dx.doi.org/10.2165/00003495-200767110-00003] [PMID: 17661527]
[59]
Chue P. Risperidone long-acting injection. Expert Rev Neurother 2003; 3(4): 435-46.
[http://dx.doi.org/10.1586/14737175.3.4.435] [PMID: 19810928]
[60]
Hosalli P, Davis JM. Depot risperidone for schizophrenia. Cochrane Database Syst Rev 2003; (4): CD004161
[PMID: 14584007]
[61]
D’Souza S, Faraj JA, Giovagnoli S, Deluca PP. Development of risperidone PLGA microspheres. J Drug Deliv 2014; 2014620464
[PMID: 24616812]
[62]
Nanaki S, Barmpalexis P, Papakonstantinou Z, Christodoulou E, Kostoglou M, Bikiaris DN. Preparation of new risperidone depot microspheres based on novel biocompatible poly (alkylene adipate) polyesters as long acting injectable formulations. J Pharm Sci 2018; 107(11): 2891-901.
[http://dx.doi.org/10.1016/j.xphs.2018.07.029] [PMID: 30096352]
[64]
Ramtoola Z, Corrigan OI, Barrett CJ. Release kinetics of fluphenazine from biodegradable microspheres. J Microencapsul 1992; 9(4): 415-23.
[http://dx.doi.org/10.3109/02652049209040480] [PMID: 1403489]
[65]
Dunne MM, Ramtoola Z, Corrigan OI. Fluphenazine release from biodegradable microparticles: characterization and modelling of release. J Microencapsul 2009; 26(5): 403-10.
[http://dx.doi.org/10.1080/02652040802396575] [PMID: 18785053]
[66]
Rupvate SR, Rokade MM, Sayyad SF, Chaudhari SR. formulation and evaluation of sustained release micro-spheres of paliperidone inventi rapid: Pharm Tech 2012.
[67]
Owen RT. Olanzapine: a review of rapid and long-acting parenteral for-mulations. Drugs of today (Barcelona, Spain: 1998) 2010; 46(3): 173-81.
[http://dx.doi.org/10.1358/dot.2010.46.3.1476499]
[68]
Frampton JE. Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia. Drugs 2010; 70(17): 2289-313.
[http://dx.doi.org/10.2165/11204930-000000000-00000] [PMID: 21080745]
[69]
Nahata T, Saini TR. Optimization of formulation variables for the development of long acting microsphere based depot injection of olanzapine. J Microencapsul 2008; 25(6): 426-33.
[http://dx.doi.org/10.1080/02652040802033913] [PMID: 18608793]
[70]
D’Souza S, Faraj JA, Giovagnoli S, Deluca PP. IVIVC from long acting olanzapine microspheres. Int J Biomater 2014; 2014 Article ID 407065
[http://dx.doi.org/10.1155/2014/407065] [PMID: 24578707]
[71]
Park C-W, Lee H-J, Oh D-W, Kang J-H, Han C-S, Kim D-W. Preparation and in vitro/in vivo evaluation of PLGA microspheres containing norquetiapine for long-acting injection. Drug Des Devel Ther 2018; 12: 711-9.
[http://dx.doi.org/10.2147/DDDT.S151437] [PMID: 29670329]
[72]
Chaudhary K, Patel MM, Mehta PJ. Long-Acting Injectables: Current Perspectives and Future Promise. Crit Rev Ther Drug Carrier Syst 2019; 36(2): 137-81.
[73]
Beresford R, Ward A. Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis. Drugs 1987; 33(1): 31-49.
[http://dx.doi.org/10.2165/00003495-198733010-00002] [PMID: 3545764]
[74]
Hemstrom CA, Evans RL, Lobeck FG. Haloperidol decanoate: a depot antipsychotic. Drug Intell Clin Pharm 1988; 22(4): 290-5.
[http://dx.doi.org/10.1177/106002808802200402] [PMID: 2897276]
[75]
Quraishi SN, David A, Brasil MA, Alheira FV. Depot haloperidol decanoate for schizophrenia. Cochrane Database Syst Rev 1999; (1):
[PMID: 10796438]
[76]
Greco K, Wright J. Aripiprazole, olanzapine and haloperidol pamoate salts 2006.
[77]
Altamura CA, Colacurcio F, Mauri MC, Moro AR, De Novellis F. Haloperidol decanoate in chronic schizophrenia: a study of 12 months with plasma levels. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14(1): 25-35.
[http://dx.doi.org/10.1016/0278-5846(90)90061-K] [PMID: 1967847]
[78]
Chouinard G, Annable L, Campbell W, Boisvert D, Bradwejn J. A Double–Blind Controlled Clinical Trial of Haloperidol Decanoate and Fluphenazine Decanoate in the Maintenance Treatment of Schizophrenia.In: Psychiatry the State of the Art, Pichot P, Ed Springer . 1985; pp. 759-61.
[http://dx.doi.org/10.1007/978-1-4613-2363-1_118]
[79]
Eberhard G, Hellbom E. Haloperidol decanoate and flupenthixol decanoate in schizophrenia. A long-term double-blind cross-over comparison. Acta Psychiatr Scand 1986; 74(3): 255-62.
[http://dx.doi.org/10.1111/j.1600-0447.1986.tb06242.x] [PMID: 3788652]
[80]
McKane JP, Robinson ADT, Wiles DH, McCreadie RG, Stirling GS. Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients. Br J Psychiatry 1987; 151(3): 333-6.
[http://dx.doi.org/10.1192/bjp.151.3.333] [PMID: 3322467]
[81]
Zissis NP, Psaras M, Lyketsos G. Haloperidol decanoate, a new long-acting antipsychotic, in chronic schizophrenics: double-blind comparison with placebo. Curr Ther Res Clin Exp 1982; 31(4): 650-5.
[82]
Deberdt R, Elens P, Berghmans W, et al. Intramuscular haloperidol decanoate for neuroleptic maintenance therapy. Efficacy, dosage schedule and plasma levels. An open multicenter study. Acta Psychiatr Scand 1980; 62(4): 356-63.
[http://dx.doi.org/10.1111/j.1600-0447.1980.tb00621.x] [PMID: 7468294]
[83]
Gelders YG, Reyntijens AJ, Ash CW, Aerts TJ. 12-month study of haloperidol decanoate in chronic schizophrenic patients. Int Pharmacopsychiatry 1982; 17(4): 247-54.
[http://dx.doi.org/10.1159/000468581] [PMID: 7185769]
[84]
Vasavan Nair NP, Suranyi-Cadotte B, Schwartz G, et al. A clinical trial comparing intramuscular haloperidol decanoate and oral haloperidol in chronic schizophrenic patients: efficacy, safety, and dosage equivalence. J Clin Psychopharmacol 1986; 6(1)(Suppl.): 30S-7S.
[http://dx.doi.org/10.1097/00004714-198602001-00006] [PMID: 3514689]
[85]
Mace S, Dzahini O, O’Hagan M, Taylor D. Haloperidol decanoate long-acting injection (HDLAI): Results of a 1-year mirror-image study. Ther Adv Psychopharmacol 2018; 8(9): 241-9.
[http://dx.doi.org/10.1177/2045125318767587] [PMID: 30181866]
[86]
Fluphenazine Decanoate FDA [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/ 071413s019lbl.pdf
[87]
Luo J-P, Hubbard JW, Midha KK. Studies on the mechanism of absorption of depot neuroleptics: fluphenazine decanoate in sesame oil. Pharm Res 1997; 14(8): 1079-84.
[http://dx.doi.org/10.1023/A:1012165731390] [PMID: 9279892]
[88]
Chue P, Chue J. A review of paliperidone palmitate. Expert Rev Neurother 2012; 12(12): 1383-97.
[http://dx.doi.org/10.1586/ern.12.137] [PMID: 23237346]
[89]
Nussbaum AM, Stroup TS. Paliperidone palmitate for schizophrenia. Schizophr Bull 2012; 38(6): 1124-7.
[http://dx.doi.org/10.1093/schbul/sbs099] [PMID: 22966147]
[90]
Paliperidone palmitate. U.S. Food and Drug Administration Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/ 2017/022264s023lbl.pdf"https:
[91]
Greenberg WM, Citrome L. Paliperidone palmitate for schizoaffective disorder: a review of the clinical evidence. Neurol Ther 2015; 4(2): 81-91.
[http://dx.doi.org/10.1007/s40120-015-0030-4] [PMID: 26662360]
[92]
Lamb YN, Keating GM. Paliperidone palmitate intramuscular 3-monthly formulation: a review in schizophrenia. Drugs 2016; 76(16): 1559-66.
[http://dx.doi.org/10.1007/s40265-016-0645-5] [PMID: 27699643]
[93]
Flupenthixol Decanoate [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/ 071413s019lbl.pdf
[94]
McCreadie RG, Flanagan WL, McKnight J, Jorgensen A. High dose flupenthixol decanoate in chronic schizophrenia. Br J Psychiatry 1979; 135(2): 175-9.
[http://dx.doi.org/10.1192/bjp.135.2.175] [PMID: 387151]
[95]
Pipotiazine Palmitate [Internet]. Available from: http://products.sanofi.ca/en/piportil-l4.pdf
[96]
Arango C, Bombín I, González-Salvador T, García-Cabeza I, Bobes J. Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence. Eur Psychiatry 2006; 21(1): 34-40.
[http://dx.doi.org/10.1016/j.eurpsy.2005.07.006] [PMID: 16360311]
[97]
Wistedt B, Koskinen T, Thelander S, Nerdrum T, Pedersen V, Mølbjerg C. Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicentre study. Acta Psychiatr Scand 1991; 84(1): 14-21.
[http://dx.doi.org/10.1111/j.1600-0447.1991.tb01414.x] [PMID: 1681680]
[98]
Zuclopenthixol Decanoate [Internet]. Available from: https://www.lundbeck.com/upload/ca/en/files/pdf/pm/Clopixol.pdf
[99]
Arif SA, Mitchell MM. Iloperidone: A new drug for the treatment of schizophrenia. Am J Health Syst Pharm 2011; 68(4): 301-8.
[http://dx.doi.org/10.2146/ajhp100079] [PMID: 21289324]
[100]
Caccia S, Pasina L, Nobili A. New atypical antipsychotics for schizophrenia: iloperidone. Drug Des Devel Ther 2010; 4: 33-48.
[http://dx.doi.org/10.2147/DDDT.S6443] [PMID: 20368905]
[101]
Ehret MJ, Sopko MA Jr, Levine A. Iloperidone: a novel atypical antipsychotic for the treatment of schizophrenia. Formulary 2008; 43(6): 190-8.
[103]
Dubey V, Saini TR. Development of long acting depot injection of Iloperidone by SABER technology. Indian J Pharm Sci 2018; 80(5): 813-9.
[http://dx.doi.org/10.4172/pharmaceutical-sciences.1000426]
[104]
Muthu MS, Agrawal P, Singh RP. Antipsychotic nanomedicine: a successful platform for clinical use. Nanomedicine 2014; 9(14): 2071-4.
[http://dx.doi.org/10.2217/nnm.14.164] [PMID: 25405791]
[105]
Kittelson DB. Engines and nanoparticles: a review. J Aerosol Sci 1998; 29(5-6): 575-88.
[http://dx.doi.org/10.1016/S0021-8502(97)10037-4]
[106]
Mohanraj VJ, Chen Y. Nanoparticles-a review. Trop J Pharm Res 2006; 5(1): 561-73.
[107]
Budhian A, Siegel SJ, Winey KI. Production of haloperidol-loaded PLGA nanoparticles for extended controlled drug release of haloperidol. J Microencapsul 2005; 22(7): 773-85.
[http://dx.doi.org/10.1080/02652040500273753] [PMID: 16421087]
[108]
Budhian A, Siegel SJ, Winey KI. Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content. Int J Pharm 2007; 336(2): 367-75.
[http://dx.doi.org/10.1016/j.ijpharm.2006.11.061] [PMID: 17207944]
[109]
Budhian A, Siegel SJ, Winey KI. Controlling the in vitro release profiles for a system of haloperidol-loaded PLGA nanoparticles. Int J Pharm 2008; 346(1-2): 151-9.
[http://dx.doi.org/10.1016/j.ijpharm.2007.06.011] [PMID: 17681683]
[110]
Benvegnú DM, Barcelos RCS, Boufleur N, et al. Haloperidol-loaded polysorbate-coated polymeric nanocapsules increase its efficacy in the antipsychotic treatment in rats. Eur J Pharm Biopharm 2011; 77(2): 332-6.
[http://dx.doi.org/10.1016/j.ejpb.2010.12.016] [PMID: 21168486]
[111]
Yasir M, Sara UVS, Som I. Haloperidol loaded solid lipid nanoparticles for nose to brain delivery: stability and vivo 2015.
[112]
Imam SS, Ahad A, Aqil M, Akhtar M, Sultana Y, Ali A. Formulation by design based risperidone nano soft lipid vesicle as a new strategy for enhanced transdermal drug delivery: In-vitro characterization, and in-vivo appraisal. Mater Sci Eng C 2017; 75: 1198-205.
[http://dx.doi.org/10.1016/j.msec.2017.02.149] [PMID: 28415407]
[113]
Kumar M, Misra A, Babbar AK, Mishra AK, Mishra P, Pathak K. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm 2008; 358(1-2): 285-91.
[http://dx.doi.org/10.1016/j.ijpharm.2008.03.029] [PMID: 18455333]
[114]
Silva AC, González-Mira E, García ML, et al. Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): high pressure homogenization versus ultrasound. Colloids Surf B Biointerfaces 2011; 86(1): 158-65.
[http://dx.doi.org/10.1016/j.colsurfb.2011.03.035] [PMID: 21530187]
[115]
Patel S, Chavhan S, Soni H, et al. Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route. J Drug Target 2011; 19(6): 468-74.
[http://dx.doi.org/10.3109/1061186X.2010.523787] [PMID: 20958095]
[116]
Muthu MS, Rawat MK, Mishra A, Singh S. PLGA nanoparticle formulations of risperidone: preparation and neuropharmacological evaluation. Nanomedicine 2009; 5(3): 323-33.
[http://dx.doi.org/10.1016/j.nano.2008.12.003] [PMID: 19523427]
[117]
Qureshi M, Aqil M, Imam SS, Ahad A, Sultana Y. Formulation and evaluation of neuroactive drug loaded chitosan nanoparticle for nose to brain delivery: in-vitro characterization and in-vivo behavior study. Curr Drug Deliv 2019; 16(2): 123-35.
[http://dx.doi.org/10.2174/1567201815666181011121750] [PMID: 30317997]
[118]
Dimer FA, Ortiz M, Pase CS, et al. Nanoencapsulation of olanzapine increases its efficacy in antipsychotic treatment and reduces adverse effects. J Biomed Nanotechnol 2014; 10(6): 1137-45.
[http://dx.doi.org/10.1166/jbn.2014.1817] [PMID: 24749408]
[119]
Vivek K, Reddy H, Murthy RSR. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles. AAPS PharmSciTech 2007; 8(4): 16-24.
[http://dx.doi.org/10.1208/pt0804083] [PMID: 18181544]
[120]
Sood S, Jawahar N, Jain K, Gowthamarajan K, Nainar Meyyanathan S. Olanzapine loaded cationic solid lipid nanoparticles for improved oral bioavailability. Curr Nanosci 2013; 9(1): 26-34.
[121]
Seju U, Kumar A, Sawant KK. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies. Acta Biomater 2011; 7(12): 4169-76.
[http://dx.doi.org/10.1016/j.actbio.2011.07.025] [PMID: 21839863]
[122]
Kumar S, Randhawa JK. Preparation and characterization of Paliperidone loaded solid lipid nanoparticles. Colloids Surf B Biointerfaces 2013; 102: 562-8.
[http://dx.doi.org/10.1016/j.colsurfb.2012.08.052] [PMID: 23104026]
[123]
Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs 2009; 18(11): 1715-26.
[http://dx.doi.org/10.1517/13543780903286388] [PMID: 19780705]
[124]
Mittapelly N, Rachumallu R, Pandey G, et al. Investigation of salt formation between memantine and pamoic acid: Its exploitation in nanocrystalline form as long acting injection. Eur J Pharm Biopharm 2016; 101: 62-71.
[http://dx.doi.org/10.1016/j.ejpb.2016.01.003] [PMID: 26850817]
[125]
Mittapelly N, Thalla M, Pandey G, et al. Long acting ionically paired embonate based nanocrystals of donepezil for the treatment of Alzheimer’s disease: a proof of concept study. Pharm Res 2017; 34(11): 2322-35.
[http://dx.doi.org/10.1007/s11095-017-2240-1] [PMID: 28808833]
[127]
Chue P, Chue J. A review of olanzapine pamoate. Expert Opin Pharmacother 2012; 13(11): 1661-70.
[http://dx.doi.org/10.1517/14656566.2012.686169] [PMID: 22746160]
[128]
Hope J, Castle D, Keks NA. Brexpiprazole: a new leaf on the partial dopamine agonist branch. Australas Psychiatry 2018; 26(1): 92-4.
[http://dx.doi.org/10.1177/1039856217732473] [PMID: 29017334]
[129]
Das S, Barnwal P, Winston A B, Mondal S, Saha I. Brexpiprazole: so far so good. Ther Adv Psychopharmacol 2016; 6(1): 39-54.
[http://dx.doi.org/10.1177/2045125315614739] [PMID: 26913177]
[130]
Campbell RH, Diduch M, Gardner KN, Thomas C. Review of cariprazine in management of psychiatric illness. Ment Health Clin 2018; 7(5): 221-9.
[http://dx.doi.org/10.9740/mhc.2017.09.221] [PMID: 29955527]
[131]
Balaraman R, Gandhi H. Asenapine, a new sublingual atypical antipsychotic. J Pharmacol Pharmacother 2010; 1(1): 60-1.
[http://dx.doi.org/10.4103/0976-500X.64538] [PMID: 21808592]
[132]
Julie KB. inventor; Eli Lilly and Co Inc., assignee. Olanzapine pamoate dihydrate. United States patent US7932249B2 2011 April..
[133]
Korinde AJ. inventor.Controlled release paliperidone composition.WO2011018246A2. 2011 Feb.
[134]
Marc KJF, Willy MACD, Esther DGB. inventor; Janssen Pharmaceutica NV Inc., assignee Aqueous suspensions of submicron 9- hydroxyrisperidone fatty acid esters United States patent US9320707B2. 2016 April;
[135]
Dierk W, Alexandra G, Markus A. inventor. Injectable depot formulation comprising crystals of iloperidone United States patent US20090099232A1. 2009 April;
[136]
Janusz WK, Takakuni M, Manoj N, Vijay HN. inventor; Otsuka Pharmaceutical Co Ltd Inc., assignee.Controlled release sterile injectable aripiprazole formulation and method. United States patent US8952013B2. 2015 Feb;
[137]
Steven JS, Karen IW, Raquel EG, Robert HL. inventor; University of Pennsylvania Inc., assignee. Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use. United States patent US8758795B2. 2014 June;
[138]
Dadhaniya TM, Sharma OP, Gohel MC, Mehta PJ. Current approaches for in vitro drug release study of long acting parenteral formulations. Curr Drug Deliv 2015; 12(3): 256-70.
[http://dx.doi.org/10.2174/1567201812666150209143731] [PMID: 25666683]


open access plus

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 1
Year: 2020
Page: [42 - 59]
Pages: 18
DOI: 10.2174/2666082216666191226143446

Article Metrics

PDF: 22
HTML: 1